What's Going On With Bluejay Diagnostics Shares On Wednesday?

Bluejay Diagnostics (BJDX) shares traded down 1.84% on Wednesday despite positive developments. The company announced a private placement raising up to $23.6 million ($8.5M upfront plus $15.1M from warrant exercises) to extend cash runway into early 2027 ahead of FDA submission. The company also partnered with Argonaut Manufacturing Services to establish U.S.-based manufacturing capabilities for its Symphony sepsis testing platform. While the stock showed strong momentum (77.52 score), the recent price action suggests caution as it approaches overbought conditions.